The DEA announced intentions to place kratom’s active compounds (mitragynine and 7-hydroxymitragynine) as Schedule I substances [1]. This emergency scheduling was based on claims that kratom posed an “imminent hazard to public safety”[1]. However, facing overwhelming public opposition including a petition with over 140,000 signatures and a letter from more than 60 members of Congress, the DEA withdrew its notice in October 2016 [2].

 

The FDA submitted a scheduling recommendation to the Department of Health and Human Services (HHS), which was formally withdrawn by HHS Assistant Secretary for Health Brett Giroir, M.D., who criticized the FDA for “disappointingly poor evidence & data and a failure to consider the overall public health” [3].

 

The Expert Committee on Drug Dependence at the World Health Organization unanimously concluded there was insufficient evidence to recommend international scheduling of kratom [3].

 

On July 29, 2025, the FDA recommended scheduling 7-hydroxymitragynine (7-OH) specifically, while explicitly stating this action would not affect natural kratom leaf products [4] [5]. This represents a shift in strategy, focusing on concentrated synthetic versions rather than the plant itself.

 

The FDA’s own research has undermined their longstanding opposition to kratom. Their Single Ascending Dose (SAD) study, presented at the Third International Kratom Symposium in February 2024, revealed findings that directly contradict the agency’s safety concerns.

 

The FDA study tested kratom doses from 1 gram to 12 grams in 40 healthy participants [6] [7]. The results were unequivocal:

 

– No serious adverse events occurred at any dose level [7]

– Kratom was deemed “well tolerated” even at extremely high doses [3]

– Only mild nausea occurred in 2 subjects at the 12-gram dose (equivalent to 24 capsules consumed in 5 minutes)[3]

– The nausea was attributed to the volume of plant material consumed rather than kratom’s pharmacological effects[6]

 

 

These findings are particularly significant because they represent the first controlled human study of kratom conducted by the FDA. The study’s conclusion that “kratom appears to be well tolerated in humans at all dose levels” directly contradicts the FDA’s public position[3].

 

Internal FDA sources reportedly expressed being “profoundly disappointed” at the lack of adverse events[8]. This reaction suggests the study was designed with the expectation of demonstrating harm, making the positive safety profile even more compelling.

 

 

7-Hydroxymitragynine (7-OH) represents one of the most potent naturally occurring opioid receptor agonists discovered, yet its history reveals important distinctions between natural occurrence and synthetic enhancement.

 

 

7-Hydroxymitragynine was first isolated and described by Ponglux et al. from Thai kratom samples[9]. Initially considered a minor alkaloid present in trace amounts.

 

Matsumoto et al. demonstrated that 7-OH possessed significantly greater analgesic potency than morphine in animal models, with ED50 values of 0.80 mg/kg (tail-flick) and 0.93 mg/kg (hot-plate) compared to morphine’s 4.57 mg/kg and 4.08 mg/kg respectively[10].

 

Kruegel et al. published landmark research in ACS Central Science demonstrating that 7-OH is an active metabolite of mitragynine, produced via CYP3A4-mediated metabolism in the liver[9]. This discovery explained kratom’s complex pharmacology and why oral administration produces different effects than expected from mitragynine’s in vitro binding profiles.

 

7-Hydroxymitragynine exhibits remarkable potency:

– 13-22 times more potent than morphine at mu-opioid receptors[11][12]

– Binding affinity: 13.5-37 nM at mu-opioid receptors[13]

– G-protein biased agonism: Does not recruit β-arrestin pathways associated with respiratory depression[14]

– Natural occurrence: Less than 0.05% of alkaloid content in natural kratom leaves[15]

 

HART Beagle Study: Methodological Flaws and Misleading Claims

 

The Holistic Alternative Recovery Trust (HART) funded beagle study represents a concerning example of how industry-sponsored research can be misrepresented to support predetermined conclusions.

 

The original protocol called for escalating doses of 10mg, 20mg, and 40mg twice daily for 7 days each[16]. However, after the **first beagle receiving the first 10mg dose experienced severe neurological events** (described as “marked central nervous system excitation followed by marked CNS depression”), researchers were forced to abandon the protocol entirely[16].

 

The study was redesigned with doses reduced by 95% to just 1mg, 2mg, and 4mg once daily[16]. This dramatic dose reduction occurred because the original dose caused what was classified as a “Serious Adverse Event”[16].

 

Despite these safety concerns, HART’s press release claimed:

– “No cardiac, neurological, or behavioral harm”

– “The only observed effect was mild, temporary drooling”

– “All animals fully recovered with no lasting impact”[16]

 

Dr. C. Michael White, Pharm.D., Chair of the Kratom Consumer Advisory Council (KCAC), reviewed the study and identified multiple misrepresentations:

– The study documented “possibly related events” including vomiting blood and mucus in feces[16]

– Risk of probable or possible adverse events with 7-OH were approximately 3-fold higher than placebo[16]

– The severe neurological event that forced protocol modification was mischaracterized[16]

 

Understanding kratom’s mechanism of action reveals why it differs fundamentally from traditional opioids and synthetic 7-OH products.

 

Mitragynine, kratom’s primary alkaloid, acts as a partial agonist at mu-opioid receptors with only 34% maximal efficacy[17]. This partial agonism creates a “ceiling effect” that limits respiratory depression risk. Additionally, mitragynine acts as a competitive antagonist at delta and kappa opioid receptors[18], potentially blocking harmful effects of more potent opioids.

 

In contrast, 7-OH acts as a full agonist at mu-opioid receptors with significantly higher potency[9]. While it maintains G-protein bias (reducing β-arrestin recruitment), its full agonism removes the safety ceiling provided by mitragynine’s partial agonism.

 

Natural kratom contains over 40 alkaloids[19] that contribute to its overall pharmacological profile:

– Speciogynine and speciociliatine: Weak antagonists that may modulate mitragynine’s effects[17]

– Corynantheidine: Partial agonist with adrenergic activity[19]

– Paynantheine: Antagonist properties at opioid receptors[17]

 

This complex alkaloid profile creates a natural “buffering” system where partial agonists and antagonists modulate the effects of more potent compounds.

 

Understanding the scope of America’s opioid crisis provides context for evaluating 7-OH’s potential impact.

 

Current Opioid Use Disorder Prevalence

 

– 2.3-3.7 million Americans** currently have opioid use disorder requiring treatment[20][21]

– 55.2% of those needing treatment actually receive it[20]

– Only 25% receive medication-assisted treatment (methadone/buprenorphine)[20]

 

 

– 37.5 opioid prescriptions dispensed per 100 persons in 2023 (down from 46.8 in 2019)[22]

– Approximately 125 million Americans received opioid prescriptions annually

– 56.5% of chronic pain patients report continuing opioid use primarily to avoid withdrawal symptoms[23]

 

 

Based on CDC and SAMHSA data, approximately 2 million Americans are actively attempting to withdraw from or reduce opioid use[20][23]. This population represents those most likely to benefit from alternative treatments like kratom.

 

 

The widespread availability of 7-OH products in convenience stores creates unprecedented access to a potent opioid-like substance.

 

 

– 152,000+ convenience stores operate in the United States[24]

– 80% sell fuel, creating high-traffic locations[24]

– 58% of fuel customers purchase items inside the store[25]

– 84% of customers consider store cleanliness when deciding to shop inside[26]

 

 

– Majority of Americans visit convenience stores at least weekly[27]

– 28% of fuel purchasers shop convenience stores daily or multiple times per week[28]

– 45% purchase beverages, 36% buy snacks during fuel stops[26]

– 91% of convenience store customers typically buy beverages[25]

 

 

Conservative estimates suggest:

– 87+ million adults regularly shop inside convenience stores during fuel stops

– 22+ million adults shop convenience stores daily or multiple times weekly

– These numbers vastly exceed the 2-3 million Americans who might benefit from 7-OH for opioid withdrawal

 

All statistics and claims in this analysis are sourced from:

 

– FDA.gov official statements and press releases[4][5]

– CDC National Center for Health Statistics[29]

– DEA official announcements[1]

– SAMHSA National Survey on Drug Use and Health[20]

 

– PubMed/NIH National Center for Biotechnology Information[9][19][17]

– ACS Central Science (American Chemical Society)[9]

– Nature Communications[30]

– Frontiers in Pharmacology[17][18]

 

– National Association of Convenience Stores (NACS)[28][24]

– Congressional Research Service reports[31]

– HHS and FDA official correspondence[3]

 

This comprehensive analysis provides documentation supporting the argument that while 7-OH may benefit a small population seeking opioid withdrawal assistance, its widespread availability in convenience stores poses risks to a vastly larger population of potential consumers who could develop dependence on this potent synthetic opioid compound.